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PPARγ isamemberoftheligand-activatednuclearreceptorsuperfamily:itsligandsactasinsulinsensitizersandsomeareapproved
for the treatment of metabolic disorders in humans. PPARγ has pleiotropic eﬀects on survival and proliferation of multiple cell
types, including cancer cells, and is now subject of intensive preclinical cancer research. Studies of the recent decade highlighted
PPARγ role as a potential modulator of angiogenesis in vitro and in vivo. These observations provide an additional facet to
the PPARγ image as potential anticancer drug. Currently PPARγ is regarded as an important target for the therapies against
angiogenesis-dependent pathological states including cancer and vascular complications of diabetes. Some of the studies, however,
identify pro-angiogenic and tumor-promoting eﬀects of PPARγ and its ligands pointing out the need for further studies. Below,
we summarize current knowledge of PPARγ regulatory mechanisms and molecular targets, and discuss ways to maximize the
beneﬁcial activity of the PPARγ agonists.
Copyright © 2008 Dorina Veliceasa et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
PPARs are nuclear hormone receptors and targets for the
compounds inducing peroxisome proliferation. The family
encompasses three species, PPARα,P P A R β/δ,a n dP P A R γ.
PPARγ, the best researched of the three, is presented by
the two isoforms, γ1a n dγ2 whereas PPARγ2 contains
30 extra amino acids at the N-terminus due to initiation
from the alternative transcription start (see Figure 1(a)).
PPARγ, a key player in adipocyte diﬀerentiation and glucose
metabolism, is abundantly expressed in adipose tissues [1].
On the other hand, it is expressed in all the cells of the
normalandpathologicalvascularbeds,includingendothelial
cells (EC), macrophages (MΦ), and vascular smooth muscle
cells (VSMCs), in a variety of tumor cells, and, at lower
levels, in lymphatic tissue, intestinal epithelium, retina,
and skeletal muscle [2]. PPARγ is a potent modulator of
the EC and VSMC function and inﬂammation: its eﬀects
on the tumor cells, tumor-associated MΦs( T A M ) ,a n d
tumor vasculature (EC and VSMCs) signiﬁcantly attenuate
tumor progression [3, 4], suggesting that PPARγ ligands
may become new convenient therapeutic modiﬁers targeting
simultaneously tumors and their microenvironment [5].
Unfortunately, recent studies reveal the tumor-promoting
and pro-angiogenic PPARγ activities; while in most cases
PPARγ agonists attenuate tumor growth and angiogenesis,
troglitazone (TGZ, a now rejected PPARγ agonist) promotes
hepatic carcinogenesis and liposarcomas. Moreover, some
PPARγ agonistspromotethediﬀerentiationofthecirculating
endothelial progenitor cells (EPC) [6] and elicit angiogenesis
in vivo [7]. In some instances, PPARγ ligands increase the
production of angiogenic stimuli, including VEGF or NO, by
theECortumorcells[8].Thus,theuseofPPARγ modulators
to manage tumor progression is more complex than it
appears at a glance and requires precise knowledge of the
molecular events involved in their pro- and antitumorigenic
actions. Below we summarize the current knowledge of
PPARγ eﬀectsandmolecularmechanismsanddelineateways
to augment PPARγ anti-angiogenic and antitumor eﬀects
while minimizing its pro-angiogenic and tumor-promoting
capacities.
2. PPARγ AND ANGIOGENESIS
Angiogenesis is a complex process involving diverse cell
types and controled by the pro- and anti-angiogenic factors2 PPAR Research
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Figure 1: PPARγ structure and regulation. (a) Schematic representation of the domain structure of the PPARγ-1 and PPARγ-2. The
mutations associated with metabolic syndrome are indicated. LF: loss of function; GF: gain of function. (b) Positive and negative regulators
of the PPARγ gene transcription. (c) The regulation of PPARγ levels by Rb and E2F. (d) The mechanism of ligand-dependent PPARγ
activation. (e) The regulation of PPARγ activity by MEK and Erk kinases: MEK1 activates Erk-1/2, which phosphorylates PPARγ and targets
it to proteasomes; in addition, MEK1 binds PPARγ in the nucleus and exports it to the cytoplasm. MEK5 can serve as coactivator for the
PPARγ.
produced by the ECs, VSMCs, and in vascular microenvi-
ronment by the stromal, tumor, and inﬂammatory cells. The
balance between positive and negative angiogenesis regu-
lators determines if the existing capillaries would expand,
regress, or remain quiescent [9]. Active angiogenesis involves
invasion, migration, and proliferation of the EC followed by
the morphogenesis (assembly) of the neovessels. It is aided
by the recruitment of the EPCs, which may constitute up to
50% of the cells in a neovessel [10]. The newly formed cap-
illaries recruit vascular smooth muscle cells (VSMCs), which
stabilize and render quiescent the newly formed capillaries:
in thus stabilized mature vessels, the interactions between
angiopoietin-1 (Ang-1) on the EC and Tie-2 receptor on
the VSMCs generate signals that dampen EC sensitivity to
the pro- and anti-angiogenic molecules [11]. Brown adipose
tissue, a thermogenic organ in mammals responds to cold
by increasing VEGF, thus creating permissive conditions
for the fat expansion. Treatment of brown adipocytes with
PPARγ ligands reduces VEGF-C mRNA pointing to their
anti-angiogenic potential [12] .M o r e o v e r ,c h i m e ri cm i c en u l l
for PPARγ show gross defects in placental vascularization
[13]. Natural and synthetic PPARγ ligands block VEGF-
driven angiogenesis in vivo, in matrigel implants, in rodent
cornea, and choroid [14–16]. RGZ suppresses the growth
and angiogenesis of the glioblastoma, Lewis lung carcinoma,
liposarcoma,andrhabdomyosarcomainmousemodels[17],
which is partly due to the PPARγ-mediated apoptosis of
the tumor EC and the repression of VEGF production by
the tumor cells. Below, we elucidate the PPARγ pleiotropic
eﬀects on angiogenesis and suggest optimization strategies.
3. PPARγ REGULATORY MECHANISMS
PPARγ can be regulated at expression level: PPARγ gene
is repressed by the GATA-2 and 3, TCF4 [18] (see
Figure 1(b)), and transactivated by CAAT enhancer binding
proteins (C/EBPs), predominantly C/EBPα, ADD1/SREBP1,
and E2F1 (see Figure 1(b)) [19]. E2F proteins have dual
eﬀect on PPARγ expression: during cell cycle progression,
phospho-Rb releases E2F1 to activate PPARγ promoter
(see Figure 1(c)), however, E2F4, if bound to the p103 or
p130Rb, represses PPARγ transcription [2, 18]. Moreover,
hypo-phosphorylated Rb binds PPARγ and recruits histoneDorina Veliceasa et al. 3
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Figure 2: Mechanisms of transrepression by PPARγ. (a) Ligand-independent repression: preferential recruitment of corepressors in the
absence of agonists. (b) Direct binding and sequestration of transcription factors on example of NFκB. (c) Activation of genes encoding
inhibitors of transcription factor (e.g., NFκB inhibitor, IκBα). (d) Direct binding and inactivation of kinases, which activate transcription
factors (e.g., the blockade of JNK activation of cJun). (e) Competitive binding of the coactivator complex. (f) The blockade of corepressor
clearance: sumoylated PPARγ stabilizes corepressor complexes (NCoR, Tab2, and TBL1) on the promoter and facilitates the recruitment of
HDAC3. In the absence of sumoylation, NCoR, Tab2, and TBL1 are subject to ubiquitination and proteasomal clearance.
deacetylase (HDAC) 3 to the complexes, causing transcrip-
tional repression (see Figure 1(c)) [19]. Multiple growth
factors including platelet-derived growth factor (PDGF),
basic ﬁbroblast growth factor (bFGF), angiotensin II, tumor
necrosis factor (TNF) α, interleukin (IL) 1β,a n dt u m o r -
derived growth factor β(TGF-β) increase PPARγ expression
by the vascular smooth muscle cells (VSMCs), via Egr-1. In
contrast, AP-1 aided by Smad3/4 represses PPARγ promoter
activity [20]. Mitotic, stress, and inﬂammatory signals cause
PPARγ degradation via phosphorylation on Ser84 of the
mouse PPARγ (Ser112 of the human molecule) in a consen-
s u sM A P Kt a r g e tm o t i fP X S P P[ 21] by ERKs, JNKs, and p38,
which leads to ubiquitination and proteasomal clearance
[22]. Ser to Ala PPARγ mutant shows increased transcrip-
tional activity, similar eﬀect is caused by coexpression of
a phosphoprotein phosphatase [21]. In human PPARγ,
substitution of proline to glutamine at position 115 results in
constitutive activation by blocking MAPK phosphorylation
at position 114: patients with such mutation display extreme
obesity [23]. Likewise, increased phosphorylation on Ser112
in Dok-1 null mice caused lean phenotype, which is lost
in mice expressing phosphorylation-defective PPARγ [24].
The eﬀect of PPARγ on angiogenesis remains to be deter-
mined.
The next regulatory step involves cofactor recruitment:
upon ligand binding, PPARγ forms heterodimers with the
retinoic acid X receptor (RXR), and occupies twin PPAR
response elements AAGGTCAnAAGGTCA (PPRE); binding
of the RXR ligands further increases transcriptional activity
of the PPARγ/RXR dimers (see Figure 1(d)). Coactivators
including SRC1, CBP/p300, pCAF/GCN, and PGC bind
PPARγ/RXR complexes in a ligand-dependent manner [19];
PGC-1α has recently been linked to HIF-independent induc-
tion of vascular endothelial growth factor (VEGF) and
angiogenesis [25]. PPARγ a c t i v i t yc a nb es u p p r e s s e dd u e
to phosphorylation, which results in nuclear export, both
executedbyMEK-1(seeFigure 1(e))[26].Incontrast,MEK-
5a c t sa sP P A R γ coactivator (see Figure 1(e)) [27].
In addition to its activator function (see Figure 1(d)),
PPARγ represses transcription of select genes. PPARγ tran-
srepression of AP-1, nuclear factor of the activated T-cells
(NFAT), NFκB, and STAT-1 is well documented [19, 28].
Typical PPARγ corepressors SMRT and NCoR corecruit
HDAC3, transducin beta-like protein-1 (TBL-1) and TBL-
1-related protein 1 (TBLR1) [29]. The repression can
be ligand-independent, with PPAR/RXR dimers forming
repressor complexes in the absence of the ligands (see
Figure 2(a)). Ligand-dependent repression may occur by4 PPAR Research
direct interaction with target transcription factors (see
Figure 2(b)), modulation of the transcriptional regulators
(see Figures 2(c) and 2(d)), by coactivator sequestration (see
Figure 2(e)), or the blockade of corepressor clearance (see
Figure 2(f)). The latter requires PPARγ sumoylation, which
keeps HDAC3 associated with repressor complexes and
prevents proteasomal clearance of their components [19].
NCoRcomplexesinteractwithalimitedsubsetofpromoters,
which explains gene-speciﬁc repression by PPARγ.
4. LIGANDS
PPARγ ligands encompass wide range of structurally
diverse compounds, natural and synthetic. Natural ones
include long chain polyunsaturated fatty acids and deriva-
tives (eicosanoids, prostaglandins, like 15-deoxy-Δ12,14-
prostaglandin J2 (15D-PGJ2)) and nitrolinoleic acids. Syn-
thetic ones include thiazolinediones (TZDs, or glitazones),
of which rosiglitazone (RGZ) and pioglitazone (PGZ) are
marketed for the treatment of type 2 diabetes and tyrosine-
based derivatives (glitazars) including tesaglitazar and far-
glitazar, the dual agonists of PPARα and PPARγ [30].
Although their ability to alleviate insulin resistance, vascular
complications, and angiogenesis is well documented, the
adverse eﬀects include hepatotoxicity, renal toxicity, weight
g a i n ,a n dﬂ u i dr e t e n t i o n[ 30], all of which complicate the
long-term use. Thus further work is required to develop
PPARγ ligands into safe and eﬃcacious treatment for
diabetes, cancer, and angiogenesis-related disease. Selective
PPARγ modulators (SPPARMs) represent one way to over-
come this problem: they are designed to retain the desired
PPARγ properties, while minimizing adverse side eﬀects.
SPPARMs can be categorized as tightly binding partial
agonists (GW0072) or weakly binding full agonists of PPARγ
(MCC-555/netoglitazone, NC-2100) [31].
5. ANTI-ANGIOGENIC EFFECTS OF PPARγ IN DIVERSE
CELL TYPES: ENDOTHELIAL-SPECIFIC EVENTS
Human micro- and macrovascular endothelial cells (EC)
express PPARγ [32]. PPARγ activation by the natural (15D-
PGJ2) or synthetic ligands (TGZ, RGZ, ciglitazone, and
pioglitazone) potently inhibits in vitro proliferation and
morphogenesis byECofdiverse tissueorigin [33].15D-PGJ2
and ciglitazone (CGZ) also induce EC apoptosis through
PPARγ-dependent pathway. The PPARγ involvement is
supported by (1) nuclear translocation, (2) increased tran-
scriptionalactivity,(3)attenuationoftheECapoptosisbythe
decoy PPRE oligonucleotide, and (4) increased background
apoptosis in PPARγ overexpressing EC, further enhanced by
the ligand exposure [15]. PPARγ activation interferes with
EC migration: TZDs block EC chemotaxis up the VEGF or
leptin gradients, by blocking PI3K/Akt and Erk1/2 signaling
[34–37]. In both cases, PPARγ/SREBP1 complex drives the
transcription of PTEN tumor suppressor, which opposes the
induction of Akt [38], see Figure 4(a).
PPARγ ligands hamper the response of the vascular EC
to VEGF by lowering VEGFR1 (Flt-1) and VEGFR2 (KDR).
The regulation of VEGFR2 is biphasic: in the absence of the
ligands, PPARγ enhances Sp1/Sp3 binding to the promoter
and opposes it if ligands are present [39]. VEGFR2 decrease
also reduces EC survival under stress or in the presence of
anti-angiogenic factors, see Figure 4(a).
PPARγ induction decreases UPA and increases PAI-1
expression by the EC, thus lowering their ability to invade
surrounding tissues [14, 16]. In the brain microvasculature,
PPARγ stimulation dampens the activation of RhoA and
Rac1 GTPases critical for the cell adhesion and migration
[40], see Figure 4(a).
Proapoptotic PPARγ eﬀects in the EC can be mediated
by p53 [41–43] or by the opening of Maxi-K channel
(Ca2+ activated K+ channel) whereas the protective Bcl-2
levels plummet and apoptotic Bax increases. In addition,
increased eNos production causes elevated NO, which, in
contrast with its usual protective eﬀect contributes to EC
death [44]. Downmodulation of the thioredoxin (Trx-1)
by PPARγ via vitamin D3 upregulated protein (VDUP-
1) also contributes to the EC killing, likely via forma-
tion of inactive PTEN/Trx-1 complexes [45]. PPARγ also
ameliorates EC activation by glucose via the induction of
diacylglycerol kinase (DGK), the reduction of diacylglycerol,
which attenuates PKC activity and decreases angiogene-
sis [46]. Importantly, PPARγ activation enhances surface
CD36, a lipid scavenger receptor, which transmits the anti-
angiogenicsignalofthrombospondin-1(TSP1)[47]apotent
endogenous inhibitor of angiogenesis, see Figure 4(a).
PPARγ produces complex eﬀect on the endothelial
progenitor cells (EPC): RGZ enhances the expression of the
endothelial markers CD31 and VEGFR2 on the circulat-
ing EPCs, however VE-cadherin and CD146 remain low;
increased uptake of oxidized lipids suggests elevated CD36,
which increases the sensitivity to TSP1. EPCs from the
diabetic patients treated with RGZ display better adherence
to ﬁbronectin than those from untreated diabetics and
normal donors [6]. This is consistent with reduced oxidative
stress and improved re-endothelialization by the EPCs from
diabetic patients in RGZ-treated mice [48]. EPCs from the
RGZ-treated diabetics migrate more vigorously than those
from untreated subjects, but similarly to the EPC from
untreated normal donors [6] suggesting that RGZ rather
normalizesthanincreasestheEPCsmigratorypotential.PGZ
eﬀectonculturedEPCsistwofold:itenhancestheexpression
of endothelial markers at a lower dose (1μm) and reduces
it at higher (10μm) concentration. PGZ also stimulates
the expression of TGFβ and TGFβ receptor [49], and thus
initiates EPC conversion to the VSMC phenotype [50]:
increased VSMC presence may stabilize the neovasculature
and thus reduce angiogenesis. This may explain why PPARγ
agonists ameliorate glomerulonephritis in mouse model
without increase in EPC homing [51].
6. IN VASCULAR SMOOTH MUSCLE CELLS
Genetic variations associated with atherosclerosis point to
PPARγ role in associated metabolic and vascular events [52].
In atherosclerotic lesions, PPARγ promotes vascular repair
and re-endothelialization, while suppressing neointima for-
mation. PPARγ attenuates vasoconstrictive remodeling byDorina Veliceasa et al. 5
blocking NADPH oxidases [53] and inhibits VSMCs pro-
liferative and migratory responses to multiple cytokines
and growth factors including PDGF-BB, bFGF, thrombin,
insulin, and angiotensin II (AngII). PPARγ interferes with
VSMC proliferation and survival by blocking the down-
stream targets of ERK1/2 and PI3K/Akt, SHIP2 and two
important regulators of mRNA translation, p70S6 kinase
and 4-EBP translation initiation inhibitor [54]. In addi-
tion, PPARγ activation enhances the expression of Shp-
2 phosphatase, which dephosphorylates/inactivates Vav, a
guanidine exchange factor for RhoA, impairs the activation
of Rho-associated kinase (ROCK), and suppresses VSMC
proliferation and migration [55]. PPARγ inhibits VSMC
migration but not the attachment and motility components
ofthemigratoryresponse:theinhibitionofPDGF-BBdriven
VSMC migration is due to the transcriptional repression of
Ets-1, which, in turn, drives MMP-9 and invasion [56], see
Figure 4(b).
PPARγ activation causes VSMC growth arrest via mul-
tiple pathways: (1) by suppressing proteasomal degradation
of the p27/Kip; (2) via transrepression of the E2F tar-
get, minichromosome maintenance protein, MCM7, which
blocks replication [2]; (3) by blocking Ets-1 dependent
transactivation of telomerase promoter [57]. PPARγ and its
agonists potently induce VSMC apoptosis (1) through direct
upregulation of GADD45 and p53 via an Oct-1 dependent
mechanism (PPRE are identiﬁed in GADD45 and p53
promoters) [58, 59]; (2) by inducing the TFG-β/ALK/Smad
pathway, subsequent Bcl-2 repression, and Smad-dependent
induction of GADD45 [60]; (3) through transcriptional
upregulation of the interferon regulatory factor-1 (IRF-1), a
proapoptotic, antiproliferative transcription factor [61], see
Figure 4(b).
All PPARγ-dependent changes in VSMC behavior can
contribute to its anti-angiogenic function: decreased VSMC
migration, and proliferation, plus increased apoptosis
restrictVSMCincorporationinthevasculatureandtherefore
the stability of neovessels. Moreover, ECs of the immature,
VSMC-poor vessels are vulnerable to the apoptotic signals
by angiogenesis inhibitors, see Figure 4(b).
7. ANTI-INFLAMMATORY EFFECTS
PPARγ aﬀects inﬂammation directly, by driving CD36-
dependent apoptosis in MΦs[ 62, 63], or indirectly, by
reducing VCAM-1 expression by the ECs and thus blocking
transendothelial migration (TEM) of monocytes and MΦs
during chronic inﬂammation typical for diabetes and cancer.
In contrast, E-selectin, a mediator of the acute immune
response, is not altered by PPARγ [64]. Statins increase
anti-inﬂammatory Cox-2 in MΦs, which, in turn, increases
endogenous 15D-PGJ2, activates PPARγ, and upregulates its
downstream target, CD36 [65]. In addition, PPARγ ligands
causeNFκBtransrepression,thusreducingtheproductionof
inﬂammatory cytokines (IL-8, IL-6, MCP-1, and CX3CL1-
1) by MΦs, and thus disrupting paracrine loop that attracts
tumor-associated MΦs( T A M )a n dt h u ss t i m u l a t e sa n g i o -
genesis and tumor growth [66], see Figure 4(c).
8. IN TUMOR CELLS AND STROMA
PPARγ is expressed in human carcinomas of the breast,
colon,esophagus,liver,lung,pancreasprostate,stomach,and
thyroid, also in neuroblastoma, astrocytoma, and glioma: in
all of these PPARγ ligands repress or delay xenograft growth
in mouse models [67].
PPARγ ligands aﬀect tumor cells in several ways: they
reduce proliferation, enhance apoptosis, and modulate
angiogenic phenotype of the tumor cells. PPARγ targets
cyclin D1 via the inhibitors of cyclin-dependent kinases
(Cdk), p18, p21, and p27, causing a decline in Rb phos-
phorylation [1] and arresting cells in G1 phase: PPARγ
acts via p21 and p27 in pancreatic cancer and via p18 in
hepatoma (see Figure 3(a)). On the other hand, glitazones
repress the production of Cdk2, 4 and 6 in carcinomas
of the bladder, breast, lung, and pancreas via GADD45
[67] (see Figure 3(b)). PPARγ activation also restores PTEN
expression intumorcellsandthusblocks PI3K/Akt axis [38],
it can also initiate a negative feedback loop, which consists
of calcineurin phosphatase, nuclear factor of the activated T-
cells(NFAT),anddownsyndromecriticalregion1(DSCR1),
which inhibits calcineurin and blocks NFAT activity neces-
sary for proliferation and survival (see Figure 3(c)) [68], see
Figure 4(c).
PPARγ induction also causes tumor cell apoptosis by
downmodulating prosurvival proteins cFLIP and Bcl-2,
while increasing proapoptotic Bax and BAD, as occurs
in glioblastoma [69] or by the interference with the
PI3K/Akt signaling [38]. Conversely, PPARγ often augments
the expression of TNF-related apoptosis inducing ligand
(TRAIL), which selectively eliminates cancer cells [70], see
Figure 4(c).
In some cases, PPARγ activation induces tumor cell
diﬀerentiation (e.g., liposarcoma, breast and pancreatic
cancer, neuroblastoma, glioma, bladder carcinoma, and lung
carcinoma). The diﬀerentiation is evidenced by the increase
of the general markers of diﬀerentiated state, such as E-
cadherin, and downregulation of the speciﬁc markers of
progenitor lineages, also by morphology changes consistent
with diﬀerentiated state (see Figure 3(d)) [1, 67].
Finally, treatment with the PPARγ ligands frequently
downregulates the expression of pro-angiogenic factors
VEGF [17], IL-8 [71], Ang-1 [72], and Cox-2 [73]a n d
thus suspends tumor angiogenesis. Moreover, mice null for
PPARγ show impaired tumorgenesis, due to the dramatic
increase in TSP-1 [5], see Figure 4(c).
9. PPARγ PRO-ANGIOGENIC/TUMORIGENIC EFFECTS
Incontrasttothemajorityofﬁndings,arecentstudysuggests
thatPPARγ ligandsmayhavepro-angiogenicpropertiesboth
invitro[74],inanendothelial/interstitialcellcocultureassay,
and in a murine corneal angiogenesis model in vivo [74].
The magnitude of the angiogenic response caused by PPARγ
ligands has not been compared to the angiogenesis elicited
by typical stimuli (VEGF, bFGF); also, the contradiction
between these results and previous studies has not yet been
addressed.6 PPAR Research
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Figure 3: PPARγ eﬀects in cancer cells. (a) The induction of Cdk inhibitor, p27 causes growth arrest due to reduced MCM7 activity
and subsequent blockade of replication. (b) The induction of GADD45 impairs Cyclin B and causes G2M growth arrest. In addition, the
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PPARγ pro-angiogenic eﬀects are associated with the
induction of VEGF and increased phosphorylation of eNOS
and AKT [7, 75], which cause elevated VEGF production
in human and rodent VSMCs, MΦs and tumor cells [76–
79], VEGF and VEGFR levels in the ECs and myoﬁbrob-
lasts [80]. Although PPARγ ligands inhibit xenografted
human tumors [1, 33], in one study using mouse model
of colon cancer (APC/Min) PPARγ ligands increased the
number of precancerous polyps, tumor frequency and size
[81]. However, in two other models, APC-deﬁcient HT-29
xenografts and azoxymetane-induced tumors PPARγ ligands
suppress tumor growth and angiogenesis [82, 83]. Of the
multiple small-scale clinical trials using PPARγ ligands for
cancer treatment, only two showed promising results: in
an early study TGZ caused prolonged PSA stabilization in
prostate cancer patients [84], while PGZ combined with
low-dose chemotherapy and rofexoxib produced moderate
improvement in the patients with high-grade glioma [85].
In contrast, patients with breast, colon, and thyroid cancers
showed no signiﬁcant response [86–88]. Thus, the use
of PPARγ ligands in clinical practice obviously requires
optimization, and the answers may come from the use of
combination or complementation treatments.
10. PPARγ LIGANDS IN COMBINATION TREATMENTS:
CAN WE AUGMENT THE BENEFICIAL EFFECTS?
The information above narrows down the list of PPARγ
targets critical for its anti-angiogenic and antitumor eﬀects
(see Figure 4(a)). PPARγ reverses angiogenic functions in
the ECs by blocking the expression of VEGF-A and its
receptor, VEGFR2 by blocking Ets-1 transcription factor,
and by dampening the prosurvival PI3K/Akt cascade, likely
via PTEN induction. It also deactivates RhoA/Rac1 small
GTPases which enable EC migration. NFAT deactivation
lowers the levels of the apoptosis inhibitors, cFLIP and
Bcl-2, and critical invasion molecules UPA and MMP 9.
In addition, PPARγ promotes the following proapoptotic
events: it elevates expression of the proapoptotic CD36 and
TSP1 receptor-ligand duo; increases p53 stability; opens
of the Maxi-K channel to upregulate nitric oxide (NO),
which, paradoxically, causes apoptosis. In addition, PPARγ
suppresses Trx-1 and ROS levels by upregulating VDUP-1,
a vitamin D3 target. Finally, PPARγ ligands block protein
synthesis via 4-eBP and p70S6 kinase, both the targets of
mTOR pathway.
In the VSMC, PPARγ represses the activation of pro-
survival Erk-1 and PI3K/Akt and SHIP thus sustaining
the unphosphorylated, active state of 4-EPB, a negative
regulator of translation. It also enhances the activity of Shp-2
phosphatase, which blocks Vav, the trigger of RhoA/ROCK
pathway necessary for survival and migration; PPARγ
also interferes with VSMC Bcl-2 expression by enhancing
TGFβ/Smad2 and disrupts MMP-9 production by blocking
Ets-1 (see Figure 4(b)).
In MΦs and tumor cells, PPARγ through transrepression
ofNFκBandNFATlowerstheproductionofmultiplegrowth
factors and inﬂammatory cytokines including VEGF, Ang-
1, cyclo-oxygenase (Cox) 2, IL-6, IL-8, MCP-1, and CX3CL-
1. PPARg also enhances the production of thrombospondin
(TSP)1:thereforeangiogenicbalancetipsinfavorofvascular
quiescence. In addition, PPARγ lowers the resistance of
tumor cells and tumor-associated MΦs (TAM) to stress and
apoptotic stimuli by blocking cyclin D1 via cdk inhibitors
p18, p21, p27, by repressing antiapoptotic Bcl-2 and FLIP, by
upregulating proapoptotic CD36 in MΦs, and Bax and BAD
in tumor cells (see Figure 4).
This comprehensive list of PPARγ targets and interacting
proteins can be used for intelligent design of the optimal
combination therapies based on PPARγ ligands to achieve
thebestanti-angiogenicandanticanceractivity.Forexample,
it stands to reason to expect that EC apoptosis caused by
PPARγ can be augmented by supplying CD36 ligand, TSP1
or its peptide mimics, such as ABT-510 [89]. Indeed, PPARγ
ligands 15PG-E2, TGZ and RGZ, and TSP1 anti-angiogenic
peptide ABT-510 synergistically block angiogenesis andDorina Veliceasa et al. 7
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Figure 4: PPARγ eﬀects on the endothelial, pericytic, tumor and immune cells in the tumor microenvironment: the consequences of
angiogenesis and possible ways to augment antitumor actions. Pro-angiogenic and tumor-promoting events are shown in red. The opposing
eﬀects are in blue. The proposed drugs are shown in black. (a) Summary of the PPARγ molecular eﬀects in the endothelial cells. TEM,
transendothelial migration. (b) PPARγ molecular eﬀe c t so nt h eV S M C s .( c )T h ee ﬀects on macrophages and tumor cells.
curtail the growth of lung and bladder carcinoma xenografts,
by initiating CD36-dependent apoptotic events in remodel-
ing tumor endothelium [47]. Furthermore, TSP1 expression
is enhanced by the low-dose metronomic chemotherapy,
including cytoxan, docetaxel, and 5-ﬂuorouracil [90–92].
Thus cytoxan, docetaxel, and 5-ﬂuorouracil are likely to
potentiate the PPARγ anti-angiogenic eﬀects in EC and to
reduce tumor-associated inﬂammation responses by killing
TAMs.Thisissupportedbythefactthat15D-PGE2 enhances
antitumor activity of docetaxel against lung carcinoma cell
lines [93]. In addition, metronomic chemotherapy enhances
the expression of Fas, a critical apoptosis mediator induced
by the TSP1/CD36 interaction and thus potentiates the
activityofTSP1derivatives,suchasABT-510[94,95].Hence,
combined use of PPARγ ligands and metronomic regimens
of chemotherapy agents is likely to be more eﬀective than
individual treatments.
PPARγ blockade of the EC and VSMC migration
involves the inhibition of RhoA/ROCK signaling [40, 65],
which makes ROCK inhibitors likely candidates for the
use in combination with PPARγ ligands. This is doubly
important, since ROCK activates Myc pathway and thus
abolishes TSP1 expression by the tumor cells [96]. ROCK
inhibitors show strong toxic eﬀects at therapeutic doses,
thus their clinical use is problematic. However, combined
use with PPARγ ligands may allow to lower their eﬀec-
tive concentration and therefore limit drug-induced toxic-
ity.
Since PPARα strongly increases TSP1 production, com-
bined use of PPARα and PPARγ agonists or the use of dual
PPARα/γ ligands may present an advantage. Interestingly,
TZD18, a novel PPARα/γ dual agonist induces apoptosis
of glioma cells with high eﬃciency [97]. Unfortunately,
glitazars have carcinogenic activity of their own [98].8 PPAR Research
PPARγ ligands sensitize leukemic, lung and endothelial
cells to the TRAIL-induced apoptosis by enhancing DR5
expression [99, 100] pointing to possible synergy between
PPARγ agonists and TRAIL therapies.
The inhibition of VEGFR2 expression by vascular
endothelium, which contributes to the antiangiogenesis by
the PPARγ, could be assisted by VEGF sequestering agents,
such as Avastin, or by the inhibitors VEGF RTK activity,
such as sunitinib, sorafenib or VEGF decoy receptor. This
hypothesis is yet to be tested.
The downstream target of the PI3K/Akt pathway, which
is blocked by PPARγ via PTEN activation, is tuberous
sclerosis tumor suppressor complex, which, when phospho-
rylated by Akt, allows the activation of mammalian target
of rapamycin (mTOR) kinase, protein synthesis, and cell
survival [101]. On the other hand, PPARγ ligands interfere
with translation by augmenting the activity of 4-EBP and
blocking S6 kinase [102]. Thus PPARγ disrupts mTOR reg-
ulation of protein synthesis at two distinct steps. Moreover,
the blockade of mTOR pathway is likely to suppress VEGF
in all cell types in the tumor microenvironment [103].
Hence, mTOR inhibitors such as tacrolimus are likely to
complement the anti-angiogenic and antitumor activity of
PPARγ agonists. Cyclic AMP analogs, which block mTOR
activity via AMPK1 pathway [101], may also contribute to
the PPARγ beneﬁcial eﬀects: this is particularly important,
since cAMP analogs are capable of increasing PPARγ activity
(Schulze-Hoepfner and Volpert, unpublished observations).
The fact that amino acid deprivation, the main oﬀ switch for
the mTOR, enhances PPARγ proapoptotic eﬀects in tumor
cells [104] lends further support to this hypothesis.
PPARγ transrepression of NFκB and NFAT signaling
leads to the inhibition of multiple angiogenic stimuli,
including interleukins 6 and 8, MCP-1 and CX3CL-1, as
well as protective Ang-1 and proinﬂammatory Cox-2. This
PPARγ function suggests a wide range of possible treatment
combinations with NFκB inhibitors, including synthetic
inhibitors of IKK kinases [105] or naturally occurring plant
substances,likecurcumin[106].Ontheotherhand,theinhi-
bition of Cox-2 with highly selective agents, like celexoxib,
has direct anti-angiogenic tumor-preventing eﬀects [107]
and is quite likely to contribute to the PPARγ antitumor
and anti-angiogenic activities, especially in the light of
potentiating eﬀect of celexoxib on docetaxel treatment [108]
and beneﬁcial eﬀects of PGZ combined with rofexoxib and
low-dose chemotherapy [85].
PPARγ activity is opposed by MEK kinases: thus MEK
inhibitors are likely to improve the eﬃcacy of PPARγ
ligands: indeed, MEK-1 inhibitor, PD98059, improves CGZ
antitumor eﬀect in colon cancer xenografts [109]. PPARγ
activity is also augmented by RXR ligands: 9-cis retinoic
acid (RA) enhances PPARγ-induced diﬀerentiation and
gene expression. In colon cancer, PPARγ and RXR ligands
induce diﬀerentiation and apoptosis more potently than
each individual compound [110, 111]. Nine-cis retinoic acid
partially overcomes RXR phosphorylation, which reduces
PPARγ/RXR dimerization and opposes PPARγ activity:
MEK-1 inhibitors improve the combined eﬀect of CGZ and
9-cis RA [109]. Finally, HDAC inhibitor, trichostatin A,
potentiates the eﬀects of phenolﬁbrate on the diﬀerentiation
and attenuation of stemness of the lung adenocarcinoma
cells [112]. While combining PPARγ agonists with other
drugs, particular attention should be paid to the ago-
nist dosage: studies of PPARγ eﬀects metabolic syndrome
demonstrate that overactive and hypoactive mutants cause
similar metabolic consequences and suggest the use of
SPPARMs versus full agonists [113].
The list of agents with the potential to enhance the
antitumor and anti-angiogenic eﬀects of PPARγ ligands
is not limited by the examples above, however we hope
that it provides a convincing example of rational design
of the complementation therapies, based on the knowledge
of molecular mediators of a given agent. The examples,
which demonstrate the improved eﬃcacy of predicted
combinations, provide an impetus for the evaluation of the
combinations, which have not yet been tested.
ABBREVIATIONS
ADD1: Adducin 1
AMPK1: Adenosine Monophosphate Protein Kinase
Ang-1: Angiopoietin-1
APC: Adenomatous Polyposis Coli
Bcl: B-cell Leukemia
bFGF: Basic Fibroblast Growth factor
C/EBPs: CAAT enhancer binding proteins
CBP: CREB binding Protein
Cdk: Cyclin-Dependent Kinases
cFLIP: FLICE Inhibitory Protein, a caspase-8 inhibitor
CGZ: Ciglitazone
Cox: Cyclooxygenase
DGK: Diacylglycerol Kinase
15D-PGJ2: 15-deoxy-Δ12,14-prostaglandin J2
DSCR1: Down Syndrome Critical Region 1
EC: Endothelial Cells
Egr: Early Growth Response
EPC: Endothelial Progenitor Cells
ERKs: Extracellular Signal-Regulated Kinase
GATA: GATA-binding transcription factor
HDAC: Histone deacetylase
HIF: Hypoxia Inducible factor
IKK: Inhibitor of Kappa Beta Kinase
IL: Interleukin
MAPK: Mitogen-Activated Protein Kinase
MCM7: Minichromosome Maintenance Protein
MCP: Monocyte Chemotactic Protein-1
MMP: Matrix Metalloproteinase
mTOR: Mammalian Target of Rapamycin
NCoR: Nuclear Co-Repressor
NADPH: Nicotinamide Dinucleotide Phosphate
NFAT: Nuclear Factor of the Activated T-cells
NFκB : N u c l e a rF a c t o rK a p p aB e t a
JNKs: Jun N-terminal Kinase
MΦ:M a c r o p h a g e s
PPAR: Peroxisome Proliferator Activated Receptor
PAI-1: Plasminogen Activator Inhibitor
PDGF-BB: Plateled-Derived Growth Factor
PI3K: Phosphatidil Inositol-3 KinaseDorina Veliceasa et al. 9
PGZ: Pioglitazone
PPRE: PPARg Response Element
PTEN: Phosphatase and Tensin Analog
Rb: Retinobalsoma
ROCK: Rho-associated kinase
RXR: Retinoic Acid X receptor
STAT: Signal Transducers and Activators of
Transcription
SMRT: Silencing Mediator of Retinoic Acid and
Thyroid Hormone Receptor
SPPARMs: Selective PPARγ modulators
SREBP: Serum response Element Binding Protein
TAM: Tumor-associated Macrophages
TBL-1: Transducin Beta-Like Protein-1
TCF: T-cell factor
TNF: Tumor Necrosis Factor
TGF-β: Tumor-Derived Growth Factor β
TGZ: Troglitazone
TRAIL: TNF-related apoptosis inducing ligand
Trx: Thioredoxin
TSP1: Thrombospondin-1
TZDs: Thiazoliediones
UPA: Urokinase Plasminogen Activator
VDUP: Vitamin D3 Upregulated Protein
VEGF: Vascular Endothelial Growth Factor
VSMC: Vascular Smooth Muscle Cells
VCAM: Vascular Cell Adhesion Molecule-1.
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